An Educational Resource by
Women's Cancer Initiative - Tata Memorial Hospital
Day 2, 12th August 2018
Methods to reduce postoperative surgical site infections after head and neck oncology surgery
Reviewer : Ramandeep Kaur
Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer
Reviewer : Sumit Gupta
Depression and survival in head and neck cancer patients
Reviewer : Poonam Joshi
How common is hypothyroidism after external radiotherapy to neck in head and neck cancer patients?
Reviewer : Nirmala Srikantia
Swallowing sparing IMRT vs Parotid sparing IMRT in head and neck cancer: Phase III randomized trial
Reviewer : Monali Swain
Sensorineural hearing loss in patients with head and neck cancer treated with chemoradiotherapy
Reviewer : Deepanjali Adulkar
Panel Discussion On Complications In Head And Neck Cancers
Moderator : Sujai Hegde
External beam radiation with or without concurrent chemotherapy in non-anaplastic thyroid cancer with unresectable or gross residual disease
Reviewer : Ashish Agrawal
Adenoid cystic carcinoma of head and neck: A single institutional analysis of 66 patients treated with multi-modality approach
Moderator : Ajeet Kumar Gandhi
Treatment-emergent hypertension and efficacy in the phase 3 study of (e7080) Levatinib in differentiated cancer of the thyroid (SELECT)
Reviewer : Joydeep Ghosh
Efficacy and safety of Vinorelbine plus Cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
Reviewer : Bharat Chauhan
Prolonged duration of response in Levatinib responders with thyroid cancers
Reviewer : Avinash Pandey
Panel Discussion On Rare HN cancers and thyroid cancers
Moderator : B. K. Smruti
1042O Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study
Reviewer : Nirmal Raut
Nivolumab vs Investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of checkmate 141 with analyses by tumor PD-L1 expression
Reviewer : Ashay Karpe
Nivolumab vs Investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck analysis of checkmate 141 by age
Reviewer : Ashay Karpe
Estimated costs of Treatment-Related Adverse Events (TRAES) for Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the checkmate 141 trial
Reviewer : Priyanka Srivastav
Health-Related Quality of Life (HRQOL) of Pembrolizumab (PEMBRO) vs Standard of Care (SOC) for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in Keynote-040
Reviewer : Sushant Mittal
Electrochemotherapy for mucosal head and neck Tumours: Results from a phase II clinical trial
Reviewer : Vinayak Maka
Interpreting indeterminate post-treatment PET/CT results in patients with head and neck squamous cell carcinoma
Reviewer : Sneha Shah
Panel Discussion On Immunotherapy and Electrochemotherapy
Moderator : Sandeep Goyle